<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-HJX9XFZ4/19c85990-8337-42ed-8c58-2570233b46e3/PDF"><dcterms:extent>322 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-HJX9XFZ4/ee209040-9630-40f3-a5bd-f34f64b67174/TEXT"><dcterms:extent>32 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-HJX9XFZ4"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2016</dcterms:issued><dc:creator>Anderluh, Franc</dc:creator><dc:creator>Anžič, Mitja</dc:creator><dc:creator>But Hadžić, Jasna</dc:creator><dc:creator>Češnjevar, Monika</dc:creator><dc:creator>Jeromen, Ana</dc:creator><dc:creator>Korošec, Peter</dc:creator><dc:creator>Oblak, Irena</dc:creator><dc:creator>Šečerov Ermenc, Ajra</dc:creator><dc:creator>Velenik, Vaneja</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:50</dc:format><dc:format xml:lang="sl">str. 113-120, VIII</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:2275963</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-HJX9XFZ4</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="en">anaemia</dc:subject><dc:subject xml:lang="en">anal canal squamous cell carcinoma</dc:subject><dc:subject xml:lang="sl">anemija</dc:subject><dc:subject xml:lang="sl">ploščatocelični analni kanal</dc:subject><dc:subject xml:lang="en">radiochemotherapy</dc:subject><dc:subject xml:lang="sl">radiokemoterapija</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin|</dc:title><dc:description xml:lang="sl">Radiochemotherapy is the main treatment for patients with squamous cell carcinoma of the anal canal. Anaemia is reported to have adverse effect on survival in cancer patients. The aim of the study was to evaluate the influence of anaemia on radiochemotherapy treatment outcome in patients with squamous cell carcinoma of the anal canal. Patients and methods. One hundred consecutive patients with histologically confirmed squamous cell carcinoma of the anal canal were treated radically with 3-dimensional conformal or intensity-modulated radiation therapy followed by brachytherapy or external beam radiotherapy boost and with concurrent mitomycin C and 5-fluorouracil. The influence on survival of pre-treatment, mean on-treatment and end-of-treatment haemoglobin (Hb) concentrations was studied. Results. The 5-year locoregional control, disease free survival, disease specific survival and overall survival rates for all patients were 72%, 71%, 77% and 62%, respectively. In univariate analysis, patients with pre-treatment and end-oftreatment Hb &gt; 120 g/L survived statistically significantly better compared to patients with Hb % 120 g/L. Patients with mean on-treatment Hb &gt; 120 g/L only had statistically significant better locoregional control and overall survival than patients with Hb % 120 g/L. In multivariate analysis, independent prognostic factors were pre-treatment Hb (&gt; 120 g/L vs. % 120 g/L) for overall survival (hazard ratio HR = 0.419, 95% confidence interval CI = 0.190%0.927, p = 0.032) and stage (I &amp; II vs. III) for disease specific (HR = 3.523, 95% CI = 1.375%9.026, p = 0.009) and overall survival (HR = 2.230, 95% CI = 1.167%4.264, p = 0.015). Conclusions. The pre-treatment, mean on-treatment and end-of-treatment Hb concentration &gt; 120 g/L carried better prognosis for patients for with squamous cell carcinoma of the anal canal treated with radiochemotherapy. The pre-treatment Hb &gt; 120 g/L was an independent prognostic factor for overall survival of patients with anal canal cancer</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-HJX9XFZ4"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-HJX9XFZ4" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-HJX9XFZ4/19c85990-8337-42ed-8c58-2570233b46e3/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-HJX9XFZ4/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-HJX9XFZ4" /></ore:Aggregation></rdf:RDF>